

## INTERNATIONAL SEARCH REPORT

National Application No  
PCT/EP 02/06389

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9842661	A		AU 6516098 A EP 0984928 A1 WO 9842661 A1 JP 2001520670 T US 6369071 B1	20-10-1998 15-03-2000 01-10-1998 30-10-2001 09-04-2002
WO 9809948	A	12-03-1998	IT MI961821 A1 AU 729533 B2 AU 4301097 A BR 9712008 A CN 1234792 A WO 9809948 A2 EP 0931065 A2 JP 2000517332 T	04-03-1998 01-02-2001 26-03-1998 24-08-1999 10-11-1999 12-03-1998 28-07-1999 26-12-2000
WO 0051988	A	08-09-2000	IT MI990413 A1 AU 3158800 A BR 0008582 A CN 1342147 T WO 0051988 A1 EP 1154999 A1 HU 0200386 A2	04-09-2000 21-09-2000 13-02-2002 27-03-2002 08-09-2000 21-11-2001 29-06-2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 December 2002 (19.12.2002)

PCT

(10) International Publication Number  
WO 02/100400 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/40, 31/60, 31/621, A61P 1/00, 7/12, 9/00, 9/08, 9/10, 9/12, 25/28, 43/00

(81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TR, TT, UA, US, UZ, VN, YU, ZA.

(21) International Application Number: PCT/EP02/05846

(22) International Filing Date: 28 May 2002 (28.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
ML2001 A 001240 13 June 2001 (13.06.2001) IT

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): NICOX S.A. [FR/FR]; 2455, routes des Dolines, Espace Gaia II - Bâtiment I, F-06906 Sophia Antipolis Cedex (FR).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventor; and

(75) Inventor/Applicant (for US only): DEL SOLDATO, Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT).

(74) Agents: SAMA, Daniele et al.; Sama Patents, Via G.B. Morgagni 2, I-20129 Milano (IT).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/100400 A1

(54) Title: ORGANIC NITRATE-BASED COMPOUNDS FOR THE TREATMENT OF VASCULOPATHIES

(57) Abstract: Use for the vasculopathy treatment of compounds or salts thereof, having the following general formula: A-(B)<sub>n</sub>-(C)<sub>2</sub>-NO<sub>2</sub> wherein A is the radical of the precursor drug selected between the salicylic or acetylsalicylic acid, B and C are bivalent linking groups as defined in the invention.

## ORGANIC NITRATE-BASED COMPOUNDS FOR THE TREATMENT OF VASCULOPATHIES

\* \* \* \* \*

The present invention relates to the use of drugs in the prevention and/or in the treatment of vasculopathies.

The most serious cardiovascular pathologies (among which thrombosis, restenosis, stroke, atherosclerosis, myocardium infarct, peripheral and central vascular diseases, etc.) are characterized by a pathological activation of vascular cells (cells of the basal smooth musculature, endothelial cells) and haematic cells (platelets, leucocytes, monocytes/macrophages, etc.).

Vasculopathies and diseases related thereto are pathological conditions associated to an altered haematochemical and clinical picture, which shows itself with hyperglycemia and/or hyperinsulinemia, hyperlipidemia and/or hydric-saline retention and/or hyperproliferation of basal and/or tumoral cells, and/or prothrombotic and procoagulative activity, etc. Vasculopathies can facilitate the onset of other pathologies such as obesity, diabetes and cardiovascular diseases such as for example myocardial, cerebral and/or peripheral ischaemias, retinopathies, polyneuropathies, gastroenteropathies, nephropathies, etc., hypertension (general and local at pulmonary, coronary, portal, renal level), atherosclerosis, Alzheimer disease, cancer.

Among vasculopathies also particular pathologies such as the X syndrome (or insulin resistance) and vasculopathy from drugs are comprised.

An unitary therapeutic approach able to prevent and/or reduce vasculopathies does not exist.

The ideal approach is to operate on the various cell processes, i.e. to prevent the pathological activation of the aforesaid cells, which leads to the onset and to the progress

of the pathological process affecting the cardiovascular system.

At present the drugs used for vasculopathies and the used therapeutical approaches inhibit only one cell population, therefore they act only on one phase of the process with only partially satisfactory results.

Statines, the rapamycin and the radiotherapeutic treatment are active only on the smooth musculature but not on the other cell populations. The results obtained with said pharmaceutical treatments and with the radiotherapy are only partially satisfactory and therefore it is necessary to increase dosages with consequent even serious side effects.

The need was felt to have available drugs allowing to carry out an effective therapeutic treatment of vasculopathies, overcoming the drawbacks associated to therapeutic and surgical treatments at present used, and being effective in inhibiting the pathological activation of different cell populations of the cardiovascular system and, besides, not resulting toxic, in particular at gastric level, and furthermore being usable for prolonged treatments without side effects.

This technical problem has now been solved by the Applicant by using a specific class of drugs. Surprisingly and unexpectedly the Applicant has found that the nitrooxyderivatives of the salicylic acid and derivatives thereof are active in the vasculopathy treatment, acting on the involved cell processes. Said result is surprising since other nitrooxyderivatives, such for example the piroxicam and ketorolac derivatives, have not proved to be active at non toxic doses. The result is still more unexpected if one considers that aspirin acts on the platelets, in a very partially way on monocytes/macrophages, and is inactive on the smooth musculature cells, on leucocytes and on endothelial cells.

An object of the present invention is the use in vasculopathies of compounds, or salts thereof, having the following general formula:



wherein:

$c_0$  is an integer and is 0 or 1;

$b_0$  is an integer and is 0 or 1, with the proviso that  $c_0$  and  $b_0$  cannot be contemporaneously equal to zero.

$A = R - C(=O)$ , wherein

$R$  is the radical of the precursor drug selected between the salicylic or acetylsalicylic acid,

$B = -T_B - X_2 - T_{B1} -$  wherein

$T_B$  and  $T_{B1}$  are equal or different;

$T_B = X$ , wherein  $X = O, S, NR_{1c}$ ,  $R_{1c}$  is H or a linear or branched alkyl, having from 1 to 5 carbon atoms;

$T_{B1} = (CO)_{tx}$  or  $(X)_{txx}$ , wherein  $tx$  and  $txx$  have the value of 0 or 1; with the proviso that  $tx = 1$  when  $txx = 0$ ,  $tx = 0$  when  $txx = 1$ ;  $X$  is as above;

$X_2$ , bivalent radical, is such that the corresponding precursor of  $B$ ,  $-T_B - X_2 - T_{B1} -$  wherein the free valence of  $T_B$  is saturated with  $Z$ , and that of  $T_{B1}$  with  $OZ$ ,  $Z$  or  $-N(Z^I)(Z^{II})$ , wherein  $Z = H, C_1 - C_{10}$ , preferably  $C_1 - C_5$  alkyl, linear or branched when possible,  $Z^I, Z^{II}$  equal or different have the  $Z$  values as above, depending on that  $T_B$  and/or  $T_{B1} = CO$  or  $X$ , in function of the values of  $t, t', tx$  and  $txx$ ;

the precursor compound of  $B$  being selected from the following:

- aminoacids, selected from the following: L-carnosine, anserine, selenocysteine, selenomethionine, penicillamine, N-acetylpenicillamine, cysteine, N-acetylcysteine, glutathione

or its esters, preferably ethyl or isopropyl ester;

- hydroxyacids, selected from the following: gallic acid, ferulic acid, gentisic acid, citric acid, caffeic, dihydrocaffeic acid, p-cumaric acid, vanillic acid;
- aromatic and heterocyclic polyalcohols, selected from the following: nordihydroguaiaretic acid, quercetin, catechin, kaempferol, sulphurethane, ascorbic acid, isoascorbic acid, hydroquinone, gossypol, reductic acid, methoxyhydroquinone, hydroxyhydroquinone, propyl gallate, saccharose, 3,5-di-tertbutyl-4-hydroxybenzylthio glycolate, p-cumaric alcohol, 4-hydroxy-phenylethylalcohol, coniferyl alcohol, allopurinol;
- compounds containing at least one free acid function, selected from the following: 3,3'-thio-dipropionic acid, fumaric acid, dihydroxymaleic acid, edetic acid;

C is the bivalent radical -T<sub>c</sub>-Y- wherein


when b<sub>0</sub> = c<sub>0</sub> = 1: T<sub>c</sub> = (CO) when t<sub>x</sub> = 0, T<sub>c</sub> = X when t<sub>xx</sub> = 0, X being as above defined;

when b<sub>0</sub> = 0: T<sub>c</sub> = (CO) when t<sub>x</sub> = 0, T<sub>c</sub> = X when t' = 0, being X as above defined;

when c<sub>0</sub> = 0: t<sub>x</sub> = 0, T<sub>Br</sub> = X = -O-;

Y is:

Y<sub>p</sub>:



(III)

wherein:

nIX is an integer between 0 and 3, preferably 1;

nIIIX is an integer between 1 and 3, preferably 1;

R<sub>TI</sub>X, R<sub>TI</sub>X', R<sub>TI</sub>IX, R<sub>TI</sub>IX', equal to or different from each other are H or linear or branched C<sub>1</sub>-C<sub>4</sub> alkyl; preferably R<sub>TI</sub>X, R<sub>TI</sub>X', R<sub>TI</sub>IX, R<sub>TI</sub>IX' are H.


Y<sup>3</sup> is a heterocyclic ring containing one or two nitrogen atoms, saturated, unsaturated or aromatic having 5 or 6 atoms,

or Y can be:


Y<sub>0</sub>, selected from the following:

- an alkyleneoxy group R'O wherein R' is a linear or branched when possible C<sub>1</sub>-C<sub>20</sub>, preferably having from 2 to 6 carbon atoms, or a cycloalkylene having from 5 to 7 carbon atoms, in the cycloalkylene ring one or more carbon atoms can be substituted by heteroatoms, the ring can have side chains of R' type, R' being as above;

or one of the following groups:




wherein  $nf'$  is an integer from 1 to 6 preferably from 1 to 4;



wherein  $R_{1f} = H, CH_3$  and  $nf'$  is an integer from 1 to 6; preferably from 1 to 4;


or  $Y$  is  $Y_{AR}$  and is selected from the following:

$Y_{AR1}$ :





wherein  $n3$  is an integer from 0 to 3 and  $n3'$  is an integer from 1 to 3;


$Y_{AR2}$ :



wherein  $n3$  and  $n3'$  have the above meaning.

Preferably  $Y^3$  is selected from the following:






Preferably Y<sup>3</sup> is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the two free valences in position 2 and 6.

The preferred of  $Y^3$  is  $Y12$  (pyridyl) substituted in position 2 and 6. The bonds can be also in unsymmetric position, for example  $Y12$  (pyridyl) can be substituted also in position 2 and 3;  $Y1$  (pyrazol) can be 3,5-disubstituted.


The precursors of  $Y_p$ , wherein the free valence of the oxygen is saturated with H and the free valence of the end carbon is saturated either with a carboxylic or an hydroxyl group, are compounds available on the market and can be obtained by methods known in the prior art.

The precursor compounds of B of the above mentioned groups are prepared according to methods known in literature and described, for example, in "The Merck Index", 12th Ed. (1996), herein incorporated by reference.

The preferred compounds of formula (I) are the following:  
 2-(acetoxy)benzoic acid (4-nitrooxy)butyl ester (X)




2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (XI)



(XI)

2-(acetyloxy)benzoic acid 4-(nitrooxymethyl)phenyl ester (XII)




(XII)

2-(acetyloxy)benzoic acid 2-(nitrooxymethyl)phenyl ester (XIII)




(XIII)

2-(acetyloxy)benzoic acid, 2-methoxy-4-[(1E)-3-[4-nitrooxy butoxy]-3-oxo-1-propenyl]phenyl ester (XIV)




(XIV)


2-(acetoxy)benzoic acid, 6-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XV)




2-hydroxy-benzoic acid, 3-(nitrooxymethyl)phenyl ester (XVI)




2-(hydroxy)benzoic acid, 4-(nitrooxymethyl)phenyl ester (XVII)



2-(hydroxy)benzoic acid, (4-nitrooxy)butyl ester (XVIII)




2-(hydroxy)benzoic acid, 2-(nitrooxymethyl)phenyl ester (XIX)




(XIX)

2-(hydroxy)benzoic acid, 2-methoxy-4-[(1*E*)-3-[4-nitrooxy butoxy]-3-oxo-1-propenyl]phenyl ester (XX)




(XX)

N-acetylcysteine, 4-nitrooxybutyl ester, 2-acetyloxy benzoate (XXI)




(XXI)

2-hydroxybenzoic acid, 6-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXII)




(XXII)

2-hydroxybenzoic acid, 5-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXIII)




(XXIII)

2-hydroxybenzoic acid, 3-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXIV)




(XXIV)

2-(acetoxy)benzoic acid, 5-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXV)




(XXV)

2-hydroxybenzoic acid, 6-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXVI)




(XXVI)

2-hydroxybenzoic acid, 5-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXVII)




(XXVII)

2-hydroxybenzoic acid, 3-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXVIII)




(XXVIII)

2-(acetoxy)benzoic acid, 5-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXIX)




(XXIX)

2-(acetoxy)benzoic acid, 3-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXX)



(XXX)

2-(acetyloxy)benzoic acid, 3-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXXI)



(XXXI)

The compounds of formula (I) are generally obtained by methods known in the prior art, see for example patent applications WO 00/61537 when in formula (I)  $b_0 = c_0 = 1$ , and WO 00/51988 and WO 95/30641 when  $b = 0$  and  $c_0 = 1$ , in the name of the Applicant.

The nitrooxyderivatives of the salicylic acid can also be synthesized starting from the corresponding nitrooxyderivatives of the acetylsalicylic acid, prepared according to the methods described in the above patent applications, by selective hydrolysis of the acetyl group. See the Examples, in particular Example 15, of the European patent application EP 01/11664 in the name of the Applicant.

When the compounds of formula (I) usable in the present invention have one or more chiral centres, they can be in a racemic form or as mixtures of diastereoisomers, as single enantiomers or single diastereoisomers; when they show geometric asymmetry, the compounds in the cis or trans form can be used.

When in the molecule of the compounds of formula (I) a salifiable functional group is present, for example an aminic or heterocyclic nitrogen, it is possible to use the corresponding salts of the above compounds, obtainable by reaction in organic solvent such as for example acetonitrile, te-

trahydrofuran, with an equimolar amount of the corresponding organic or inorganic acid.

Examples of usable organic acids are the following: oxalic, tartaric, maleic, succinic, citric acid.

Examples of usable inorganic acids are the following: nitric, hydrochloric, sulphuric, phosphoric acid. Nitric and hydrochloric acids are preferred.

By using the products of the invention, the vasculopathy is significantly reduced and in particular the restenosis process which can arise in people subjected to angioplasty and in particular in those more at risk such as old people, diabetic, hyperlipidemic people.

The therapeutic use of the compounds described in the present invention results advantageous, as said, since these compounds are able to act both on the duct (endothelial and vasal smooth musculature cells) and on the haematic cells (platelets, leucocytes) and haematic factors.

The compounds of formula (I) are formulated in the corresponding pharmaceutical compositions for parenteral, oral use according to the techniques well known in the prior art, together with the usual excipients; see for example the volume "Remington's Pharmaceutical Sciences" 15th Ed.

The amount on a molar basis of the active principle in said formulations is equal to or lower than the maximum posology indicated for the precursor drugs. Also higher doses can be used in consideration of their very good tolerability. The daily doses of the precursor drugs can be found in the publications of the prior art, such as for example in "Physician's Desk Reference".

The following Examples illustrate the invention and are not limitative of the scope of the same.

**EXAMPLE F1**

Efficacy of Aspirin and of 2-acetyloxybenzoic acid (3-nitrooxymethyl)phenyl ester (formula XI), in an experimental model of restenosis induced in rats

The aspirin ester (NO-Aspirin), has been synthesized as described in Example 3 of patent application WO 97/16405.

In comparative compounds were used aspirin, the 5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-carboxylic acid (4-nitrooxy)butyl ester (NO-ketorolac), synthesized as described in Example 1F of patent application WO 95/30641, ketorolac.

Male Wistar rats weighing 300-350 g were anaesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (5 mg/kg) and subjected to angioplasty according to the procedure described by Indolfi et Al., Circulation, 1995, 92, 1230-1235, by using a little balloon catheter which was first introduced in the aortic arch through the right carotid, then swollen and then let pass three times forth and back in the duct lumen.

The rats were divided in the indicated groups (n. 12 animals each) and subjected to pharmacological treatment as described hereunder for the 14 days following the vascular damage. The compounds, dissolved in polyethylenglycol (PEG 400) were administered by os by gastric probe according to the following scheme:

- 2 groups received NO-Aspirin at the dose of 30 and 100 mg/kg, respectively,
- 2 groups received Aspirin at the dose of 16 and 54 mg/kg, respectively,
- 1 group received NO-Ketorolac at the dose of 10 mg/Kg,
- 1 group received Ketorolac at the dose of 5 mg/Kg,

- the control group received only the carrier (PEG 400, 0.2 ml/rat).

At the end of the treatment the animals were anaesthetized as described above and the carotids were first washed by infusion, through the left ventricle, of saline buffer phosphate (PBS, pH 7,2, 100ml) then fixed with PBS containing paraformaldehyde (4%).

The animals were sacrificed and the carotids removed. For each artery n. 6 sections having a thickness of 6  $\mu\text{m}$  were isolated. Stomachs were removed and inspected for damages of the gastric mucosa, determining the areas of both bleeding lesions and non bleeding lesions. Said lesions were evaluated by a score according to known methods.

3 of the 6 sections of each artery were stained with hematoxylin and eosin to evidence different types of cells, the remaining 3 sections were stained first with aldehyde fuchsin and then with the Gieson solution to evidence the internal elastic lamina (IEL). The sections were photographed and the imagines were analyzed by an image analysis system (Qwin Lite, Leica, Milan).

The thicknesses respectively of the middle and neointima tunica, and of the duct wall were measured. The results reported in Table 1 are expressed as percentage of restenosis and have been calculated as a ratio between the thickness of the neointima tunica and that of the middle tunica (M/N) measured in the sections obtained from the groups, assuming equal to 100 the N/M ratio of the control group.

The results reported in Table 1 show that the formation of the neointima tunica in the vascular wall caused by the lesion with the little balloon catheter is already significantly reduced when administering low doses of NO-aspirin. On the contrary it is necessary to administer high doses of

Aspirin (comparison), which however produce lesions to the gastric mucosa, to obtain a small reduction of the restenosis. NO-Ketorolac (comparison) appears not very effective and shows a gastric toxicity.

**EXAMPLE F2**

Evaluation of the mortality in SP-SHR rats (stroke-prone spontaneously hypertension rats) treated with 2-acetyloxybenzoic acid (6-nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (formula XV), (NO-ASA) and Aspirin.

The NO-ASA compound has been synthesized according to the Example 1 of European Pb. No. 1,154,999.

In this experiment SP-SHR rats were used which develop a severe hypertension, with a high incidence of spontaneous cerebral infarct. In said rats the pathogenesis of the cerebral ischaemia has been found to be predictive of the human pathology. (Yamori Y. et al. Stroke 1976; 7: 46-53).

Three groups each formed by 12 SP-SHR rats, 8 weeks old at the beginning of the experiment, received for 16 weeks together with the daily diet Aspirin (54 mg/kg) NO-ASA (30 mg/kg); the control group received only the diet.

During the period of chronic treatment the percentage of animal survival was evaluated.

The results are reported in Table 2 and show that at the tenth week all the animals of the control group had died, while in that treated with NO-ASA, also at the sixteenth week, deaths due to cerebral infarct were not noticed.

**EXAMPLE F3**

Evaluation of the vascular damage in animals treated with NO-ASA and Aspirin

In this experiment SP-SHR rats were used, as in the previous Example.

Three groups, each formed by 12 SP-SHR rats, 8 weeks old at the beginning of the experiment, received respectively for 6 weeks, together with the daily diet Aspirin (54 mg/kg) NO-ASA (30 mg/kg) (two groups); the control group (third group) received only the diet.

At the end of the treatment the animals were sacrificed by decapitation and the carotids were isolated. The ducts were opened and washed with cold sterile buffer phosphate (PBS) containing EDTA (2mM) and maintained in cold PBS (cooled in ice bath) containing 2, [6]-di-tert-butyl-p-cresol (50  $\mu$ M), aprotin (0.001%), EDTA (50mM) and chloramphenicol (0.008%). The arteries were fixed with formalin (10%), then soaked in paraffin and then dissected. An aliquot of the obtained sections was incubated with MDA2 antibodies, which are directed against specific epitopes for oxidized LDL.

The obtained results are reported in Table 3. The data were calculated by considering the number of the sections, positive at the immunohistochemical test with MDA2 antibodies, detected in the groups of the treated animals and in the control group, respectively. The results are expressed as percentage of reduction of the oxidized LDL (low density lipoprotein) presence in the vascular wall taking as 0 the LDL value measured in the control group.

The oxidized lipoprotein content was found to be correlated with the severity of the disease and the mortality incidence in the treated. This datum is therefore of particular importance.

The reduction of oxidized LDL is an index of the vasal protection from thrombogenic damage which is the triggering factor of cerebral infarct.

Table 1

Activity of the compounds of the Example FD1 on the restenosis experimentally caused by balloon angioplasty and evaluation of the damages to the gastric mucosa caused by administering the tested compounds (* = p<0.05 vs controls)				
Compounds	Dose (mg/Kg)	Restenosis %	Dose (mg/Kg)	Gastric damage Score
Control	--	100	--	2
NO-Aspirin	30	62.5*	166	2
NO-Aspirin	100	31*	249	4
Aspirin	16	100	50	22*
Aspirin	54	55*	100	42*
NO Ketorolac	10	90	10	20
Ketorolac	5	100	5	50

Table 2

Evaluation of the mortality in SP-SHR rats treated with (NO-ASA) and Aspirin for 16 weeks			
Treatment	Dose , (mg/kg/die)	X <sup>th</sup> week	XVI <sup>th</sup> week
		% of survival	
Controls	-	0	0
NO-ASA	30	100	100
Aspirin	54	100	50

Table 3

Evaluation of the vascular damage in carotids of rats treated with NO-ASA and Aspirin, determined as reduction % of the presence of oxidized LDL in the vascular wall		
Treatment	Dose (mg/kg)	reduction % of the presence of oxidized LDL
Controls	-	0
NO-ASA	30	74
Aspirin	54	19

## CLAIMS

1. Use for preparing drugs for vasculopathy treatment of compounds, or salts thereof, having the general formula:



wherein:

$c_0$  is an integer and is 0 or 1;

$b_0$  is an integer and is 0 or 1, with the proviso that  $c_0$  and  $b_0$  cannot be contemporaneously equal to zero.

$A = R-C(=O)$ , wherein

$R$  is the radical of the precursor drug selected from the salicylic or acetylsalicylic acid,

$B = -T_B-X_2-T_{BI}-$  wherein

$T_B$  and  $T_{BI}$  are equal or different;

$T_B = X$ , wherein  $X = O, S, NR_{1c}, R_{1c}$  is H or a linear or branched alkyl having from 1 to 5 carbon atoms;

$T_{BI} = (CO)_{tx}$  or  $(X)_{txx}$ , wherein  $tx$  and  $txx$  have the value of 0 or 1; with the proviso that  $tx = 1$  when  $txx = 0$ ,  $tx = 0$  when  $txx = 1$ ;  $X$  is as above;

$X_2$ , bivalent radical, is such that the corresponding precursor of  $B$ ,  $-T_B-X_2-T_{BI}-$  wherein the free valence of  $T_B$  is saturated with  $Z$ , and that of  $T_{BI}$  with  $OZ$ ,  $Z$  or with  $-N(Z^I)(Z^{II})$ , wherein  $Z = H, C_1-C_{10}$ , preferably  $C_1-C_5$  alkyl, linear or branched when possible,  $Z^I, Z^{II}$  equal or different have the  $Z$  values as above, depending on that  $T_B$  and/or  $T_{BI} = CO$  or  $X$ , in function of the values of  $t, t', tx$  and  $txx$ ; the precursor compound of  $B$  being selected from the following:

- aminoacids, selected from the following: L-carnosine, anserine, selenocysteine, selenomethionine, penicillamine, N-acetylpenicillamine, cysteine, N-acetylcysteine, glutathione or its

esters, preferably ethyl or isopropyl ester;

- hydroxyacids, selected from the following: gallic acid, ferulic acid, gentisic acid, citric acid, caffeic acid, dihydrocaffeic acid, p-cumaric acid, vanillic acid;
- aromatic and heterocyclic polyalcohols, selected from the following: nordihydroguaiaretic acid, quercetin, catechin, kaempferol, sulphurethyne, ascorbic acid, isoascorbic acid, hydroquinone, gossypol, reductic acid, methoxyhydroquinone, hydroxyhydroquinone, propyl gallate, saccharose, 3,5-di-tertbutyl-4-hydroxy-benzylthio glycolate, p-cumaric alcohol, 4-hydroxy-phenylethylalcohol, coniferyl alcohol, allopurinol;
- compounds containing at least one free acid function, selected from the following: 3,3'-thiodipropionic acid, fumaric acid, dihydroxymaleic acid, edetic acid;

C is the bivalent radical -T<sub>c</sub>-Y- wherein


when b<sub>0</sub> = c<sub>0</sub> = 1: T<sub>c</sub> = (CO) when t<sub>x</sub> = 0, T<sub>c</sub> = X when t<sub>xx</sub> = 0, X being as above defined;

when b<sub>0</sub> = 0: T<sub>c</sub> = (CO) when t<sub>x</sub> = 0, T<sub>c</sub> = X when t' = 0, being X as above defined;

when c<sub>0</sub> = 0: t<sub>x</sub> = 0, T<sub>BI</sub> = X = -O-;

Y is:

$y_p:$



(III)

wherein:

nIX is an integer between 0 and 3, preferably 1;

nIIX is an interger comprised between 1 and 3, preferably 1;

$R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIIX}$ ,  $R_{TIIIX'}$ , equal to or different from each other are H or linear or branched  $C_1-C_4$  alkyl; preferably  $R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIIX}$ ,  $R_{TIIIX'}$  are H;


$Y^3$  is an heterocyclic ring containing one or two nitrogen atoms, saturated, unsaturated or aromatic, having 5 or 6 atoms,

or Y can be:


$Y_0$ , selected from the following:

- an alkyleneoxy group  $R'O$  wherein  $R'$  is a linear or branched when possible  $C_1-C_{20}$  alkyl, preferably having from 2 to 6 carbon atoms, or a cycloalkylene having from 5 to 7 carbon atoms, in the cycloalkylene ring one or more carbon atoms can be substituted by heteroatoms, the ring can have side chains of  $R'$  type,  $R'$  being as above;

or one of the following groups:




wherein  $nf'$  is an integer from 1 to 6 preferably from 1 to 4;



wherein  $R_{1f} = H, CH_3$  and  $nf'$  is an integer from 1 to 6; preferably from 1 to 4;


or  $Y$  is  $Y_{AR}$  and is selected from the following:

$Y_{AR1}$ :




wherein  $n3$  is an integer from 0 to 3 and  $n3'$  is an integer from 1 to 3;

$Y_{AR2}$ :



wherein  $n3$  and  $n3'$  have the above meaning.

2. Use according to claim 1, wherein  $Y^3$  in formula (III) is selected from the following:



(Y1)


(Y2)

(Y3)

(Y4)

(Y5)

(Y6)




(Y7)

(Y8)

(Y9)


(Y10)

(Y11)




3. Use according to claim 2, wherein  $Y^3$  is an aromatic ring having 6 atoms, containing one nitrogen atom and having the two free valences respectively in position 2 and 6.
4. Use according to claims 2-3, wherein  $Y^3$  is Y12 (pyridyl) substituted in position 2 and 6.
5. Use according to claims 1-4, wherein the compounds are the following:

2-(acetyloxy)benzoic acid (4-nitrooxy)butyl ester  
(X)




(X)

2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (XI)




(XI)

2-(acetyloxy)benzoic acid 4-(nitrooxymethyl)phenyl ester (XII)




(XII)

2-(acetyloxy)benzoic acid 2-(nitrooxymethyl)phenyl ester (XIII)




(XIII)

2-(acetyloxy)benzoic acid, 2-methoxy-4-[(1E)-3-[4-nitrooxy butoxy]-3-oxo-1-propenyl]phenyl ester (XIV)




(XIV)

2-(acetyloxy)benzoic acid, 6-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XV)




(XV)

2-hydroxy-benzoic acid, 3-(nitrooxymethyl)phenyl ester (XVI)




(XVI)

2-(hydroxy)benzoic acid, 4-(nitrooxymethyl)phenyl ester (XVII)




(XVII)

2-(hydroxy)benzoic acid, (4-nitrooxy)butyl ester (XVIII)




(XVIII)

2-(hydroxy)benzoic acid, 2-(nitrooxymethyl)phenyl ester (XIX)




(XIX)

2-(hydroxy)benzoic acid, 2-methoxy-4-[(1E)-3-[4-nitrooxy butoxy]-3-oxo-1-propenyl]phenyl ester (XX)




(XX)

N-acetylcysteine, 4-nitrooxybutyl ester, 2-acetyloxy-benzoate (XXI)




(XXI)

2-hydroxybenzoic acid, 6-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXII)




(XXII)

2-hydroxybenzoic acid, 5-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXIII)




(XXIII)

2-hydroxybenzoic acid, 3-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXIV)




(XXIV)

2-(acetyloxy)benzoic acid, 5-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXV)




(XXV)

2-hydroxybenzoic acid, 6-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXVI)




(XXVI)

2-hydroxybenzoic acid, 5-(nitrooxymethyl)-2-methyl pyridinyl hydrochloride ester (XXVII)




(XXVII)

2-hydroxybenzoic acid, 3-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXVIII)




(XXVIII)

2-(acetoxy)benzoic acid, 5-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXIX)




(XXIX)

2-(acetoxy)benzoic acid, 3-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXX)



(XXX)

2-(acetoxy)benzoic acid, 3-(nitrooxymethyl)-2-methylpyridinyl hydrochloride ester (XXXI)



(XXXI)

6. Use according to claims 1-5, wherein the compounds or their salts are used in the corresponding pharmaceutical formulations for parenteral, oral and topical use.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/05846

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 A61K31/40 A61K31/60 A61K31/621 A61P1/00 A61P7/12 A61P9/00 A61P9/08 A61P9/10 A61P9/12 A61P25/28 A61P43/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS					
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
X	WO 95 30641 A (NICOX LTD ;DEL SOLDATO PIERO (IT); SANNICOLO FRANCESCO (IT)) 16 November 1995 (1995-11-16) cited in the application abstract page 1, line 1 - line 2 page 5, paragraph 4 -page 6, paragraph 3 page 55 -page 58 claims 1-7 --- WO 97 16405 A (NICOX SA ;DEL SOLDATO PIERO (IT); SANNICOLO FRANCESCO (IT)) 9 May 1997 (1997-05-09) cited in the application abstract page 1, paragraph 1 - paragraph 4 page 16 -page 18 claims 1-6 --- -/-				5,6
X					5,6
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.					
* Special categories of cited documents : 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed					
*T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family					
Date of the actual completion of the international search			Date of mailing of the international search report		
18 September 2002			11/10/2002		
Name and mailing address of the ISA			Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016			Taylor, G.M.		

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/05846

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 51988 A (NICOX SA ;DEL SOLDATO PIERO (IT); BENEDINI FRANCESCA (IT)) 8 September 2000 (2000-09-08) cited in the application abstract page 1, paragraph 1 - paragraph 3 example 15 claims 1-14 ---	5,6
X	WO 00 61537 A (NICOX SA ;DEL SOLDATO PIERO (IT)) 19 October 2000 (2000-10-19) cited in the application abstract page 1 -page 3 claims 1-10 ---	5,6
P,X, L	WO 02 30866 A (NICOX SA ;ANTOGNAZZA PATRIZIA (IT); DEL SOLDATO PIERO (IT); BENEDI) 18 April 2002 (2002-04-18) abstract page 1, paragraph 1 -page 2, paragraph 6 pharmacological examples claims 1-10 L: Priority ---	5,6
P,X, L	WO 02 30867 A (NICOX SA ;DEL SOLDATO PIERO (IT)) 18 April 2002 (2002-04-18) abstract page 1, paragraph 1 pharmacological examples claims 1-17 L: Priority ---	5,6
A	FIORUCCI, S. ET AL.: "An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 98, no. 5, 27 March 2001 (2001-03-27), pages 2652-2657, XP001105097 abstract last paragraph page 2657 ---	5,6
	-/-	

## INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/05846

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WALLACE, J.L ET AL.: "Nitric oxide-releasing NSAIDs: GI-safe antithrombotics" IDRUGS, vol. 2, no. 4, 1999, pages 321-326, XP001105153 abstract introduction antihypertensive effects conclusion -----</p>	5,6